Compare NKE & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NKE | REGN |
|---|---|---|
| Founded | 1964 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Shoe Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 94.6B | 79.4B |
| IPO Year | 1995 | 1995 |
| Metric | NKE | REGN |
|---|---|---|
| Price | $54.02 | $746.39 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 26 | 24 |
| Target Price | $76.83 | ★ $819.54 |
| AVG Volume (30 Days) | ★ 13.0M | 559.3K |
| Earning Date | 03-19-2026 | 01-01-0001 |
| Dividend Yield | ★ 3.03% | 0.50% |
| EPS Growth | N/A | ★ 8.19 |
| EPS | 1.03 | ★ 41.48 |
| Revenue | ★ $46,309,000,000.00 | $5,872,227,000.00 |
| Revenue This Year | $1.76 | $11.69 |
| Revenue Next Year | $3.90 | $10.06 |
| P/E Ratio | $52.51 | ★ $17.98 |
| Revenue Growth | N/A | ★ 20.82 |
| 52 Week Low | $52.28 | $476.49 |
| 52 Week High | $80.17 | $821.11 |
| Indicator | NKE | REGN |
|---|---|---|
| Relative Strength Index (RSI) | 25.10 | 42.37 |
| Support Level | N/A | $740.39 |
| Resistance Level | $64.21 | $788.69 |
| Average True Range (ATR) | 1.33 | 21.98 |
| MACD | -0.77 | -4.12 |
| Stochastic Oscillator | 2.61 | 6.97 |
Nike is the largest athletic footwear and apparel brand in the world. Footwear generates about two-thirds of its sales. Key performance footwear categories include basketball, running, and football (soccer). Its brands include Nike, Jordan (premium athletic footwear and clothing), NikeSkims (women's athleisure), and Converse (casual footwear). Nike sells products worldwide through company-owned stores, franchised stores (including about 5,500 in China), and third-party retailers. The firm also operates e-commerce platforms in more than 40 countries. Nearly all its production is outsourced to contract manufacturers in more than 30 countries. Nike was founded in 1964 and is based in Beaverton, Oregon.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).